Jun 24, 2013 by Dave WilliamsonObamacare-Fueled Hospital Takeovers Begin Tenet buys Vanguard for $1.7 billion, a 70% premium.
Jun 23, 2013 by Dave WilliamsonWhat the Supreme Court's Pay-for-Delay Decision Means for InvestorsTaking a closer look at the high court's decision and how it affects Big Pharma and generic-drug maker stocks.
Jun 20, 2013 by Dave WilliamsonBiotech IPO a Buy or a Bubble Warning?Why investors are excited about Bluebird Bio's stock market debut.
Jun 19, 2013 by Dave Williamson3 Blood Cancer Drug Hopefuls in the SpotlightTaking a look at three prominent blood cancer drugs post-ASCO conference.
Jun 14, 2013 by Dave WilliamsonNew Challenger Takes on Healthcare HeavyweightsPharmacy benefits manager Catamaran locks up Cigna's business for 10 years.
Jun 12, 2013 by Dave WilliamsonQuestcor Pop: Acquisition Trumps CompetitionQuestcor buys out potential competition from Novartis Synacthen and shares surge.
Jun 12, 2013 by Dave WilliamsonThe Best Kind of Biotech DilutionClovis hits capital markets, but 300% year-to-date gains has most investors smiling.
Jun 11, 2013 by Dave WilliamsonThe Obesity-Drug Wars Officially BeginWith Arena's Belviq is finally commercially available, the obesity drug wars can start.
Jun 11, 2013 by Dave WilliamsonGame-Changing Hep C Pill Closer to ApprovalGilead gets FDA priority review status for its game-changing hepatitis C drug.
Jun 5, 2013 by Dave WilliamsonObamacare Fuels Hospital Takeover SpeculationCommunity Health looks for a big aquisition as leaderless Health Managment looks like a target.
Jun 3, 2013 by Dave Williamson1 Biotech + 2 Cancer Drugs = 100% PopHow new exciting cancer drugs for lung, ovarian, and breast cancer caused big stock pops.
Jun 1, 2013 by Dave WilliamsonWhy Insurers Continue to Shun Obamacare's ExchangesA closer look at how the insurance industry is adapting to Obamacare.
May 31, 2013 by Dave WilliamsonEurope is Positive on these 2 DrugsCelgene's pomalidomide and Aegerion's Juxtapid get positive opinions from the CHMP
May 30, 2013 by Dave Williamson2 New Melanoma Drugs and 1 Vaccine AcquisitionGlaxoSmithKline isn't sitting still, with two cancer drug approvals and some M&A.
May 30, 2013 by Dave WilliamsonHigh Drama for This High-Triglyceride FighterDid Elan just let it slip that it's interested in Amarin?
May 29, 2013 by Dave WilliamsonSeeing Is Believing With This Blockbuster Eye DealValeant buys venerable eye-care company Bausch & Lomb.
May 27, 2013 by Dave Williamson2 Biotech Stocks in Activist Investors' CrosshairsForest Labs and obesity drugmaker VIVUS find themselves targets of Carl Icahn and First Manhattan, respectively.
May 26, 2013 by Dave WilliamsonNew Pancreatic Cancer Drug an FDA PriorityCelgene's abraxane has recieved a priority review from the Food and Drug Administration.
May 26, 2013 by Dave WilliamsonThe Hidden Danger of Car ExhaustA study links diesel exhaust fumes to cholesterol problems and damaged arteries.
May 22, 2013 by Dave WilliamsonInvest in Your Pets for LessLike any good Memorial Day sale, Pfizer sells its 80% stake in Zoetis at a 7% discount
